5 terminated. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 5 |
| Phase 2 | 1 | Terminated 1 |
Follow Refractory Malignant Solid Neoplasm: new trials by email Literature Review of Refractory Malignant Solid Neoplasm trials Research Report on Refractory Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide, Etoposide - Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 12 | 2018-08-31 | 2026-03-20 |
| Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors Navitoclax, Vistusertib - Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2018-03-20 | 2023-10-17 |
| Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Everolimus, Neratinib, Palbociclib - Advanced Malignant Solid Neoplasm, EGFR Gene Amplification | Phase 1 | Terminated | M.D. Anderson Cancer Center | 84 | 2017-10-31 | 2026-07-22 |
| Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer Chemotherapy, Disulfiram, Gemcitabine Hydrochloride - Metastatic Pancreatic Adenocarcinoma, Refractory Malignant Solid Neoplasm | Phase 1 | Terminated | Mayo Clinic | 16 | 2016-02-25 | 2025-01-07 |
Neoplasm Metastasis (3) · Pancreatic Neoplasms (2) · Anemia (1) · Blast Crisis (1) · Bone Neoplasms (1) · Breast Neoplasms (1) · Endocrine Gland Neoplasms (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1) · Leukemia, Myeloid, Chronic-Phase (1)
Neoplasms (5) · Neoplasms by Site (4) · Endocrine System Diseases (3) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Lung Diseases (2) · Lung Neoplasms (2) · Male Urogenital Diseases (2) · Neoplasms by Histologic Type (2) · Pancreatic Diseases (2) · Respiratory Tract Diseases (2)
Everolimus (2) · neratinib (2) · palbociclib (2) · trametinib (2) · 130-nm albumin-bound paclitaxel (1) · 2C4 antibody (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Bortezomib (1) · CTLA-4 Antigen (1) · Capecitabine (1) · Carboplatin (1) · Celecoxib (1)
M.D. Anderson Cancer Center (2) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1)
United States (5)
Aminah Jatoi, M.D. (1) · Christine L Hann (1) · Demetrios Petropoulos (1) · Lara Davis, MD (1) · Sarina A Piha-Paul (1)
PMID 37314501, PMID 39863139, PMID 39998620
P30CA016672 (1), R01CA195473 (1), UM1CA186691 (1)